When considering the 62 genes intersecting between treatment and outcomes, we further found enrichment for cardiomyopathy (strength = 1.16, FDR = 0.025), oxytocin signalling (strength = 0.93, FDR = 0.043), epidermal growth factors (strength = 0.88, FDR = 0.035) and several biological processes and cellular components (supplement S4). This evidence concerns the gene OXT and cardiomyopathy.